

Seeking Druggable Targets for Weight Loss

Over 140 years and nearly 100 medicines later, **Eli Lilly** keep looking for the next great discovery and for even more ways to make life better for people around the world. The Eli Lilly team are currently looking for **druggable targets for weight loss**. In particular, the team are looking for **approaches focused on appetite modulation, energy expenditure, and mechanisms synergistic with GLP-1**.



Approaches of Interest:

- **Approaches for weight loss** in general, even unrelated to diabetes. Weight loss due to side effects, for example, may not be productive unless it would provide insight into cachexia-like pathways
- **Focus on the induction of weight loss and/or maintenance**
- **Exclusively drug research surrounding weight loss**
- Interest in **any pathway related to weight loss**, not exclusive to GLP-1
- Open to different modalities including **small molecules, biologics, and gene therapy**
- **Drug repurposing** is also of interest if it has associated intellectual property
- Agents that induce significant weight loss **do not necessarily require to have a major impact on diabetic parameters (e.g., glycemia or insulin sensitivity)** to be of interest for this campaign

Out of Scope:

- Plant/food-based approaches
- Probiotics or microbiome targeting unless weight loss is strikingly robust

Developmental Stages of Interest:

- Opportunities at basic research phase to late-stage clinical trial are within scope
- For opportunities at the basic research stage, target validation is required in some way
- All types of validation are of interest e.g., *in vivo*, *in vitro* or *ex vivo* validation models






Submission Information:

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration:

Eli Lilly is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **5th September 2022 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk



Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.